Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 29, 2022 3:31pm
66 Views
Post# 34556475

RE:RE:RE:RE:RE:RE:RE:More on Reverse Splits

RE:RE:RE:RE:RE:RE:RE:More on Reverse SplitsI am sure they do other things. I am sure they have talks with potential partners, financial firms, investors, potential investors, cancer experts, and so on. That being said, at this point they don't have much to discuss. They can only discuss hypothetical scenarios since they cannot disclose what they have right now in phase Ia. I think preliminary contacts have been made with all the relevant people, but they will be able to get real only with real reasults. I always come back to this basic point, a good seller is someone with something good to sell. Now they don't have that, or if they have it, they cannot talk about it. I am sure they have a plan in place to be very active if they have something meaningful in their hand, or something that would lead them to think they are on the right path to get that in phase Ib.


SPCEO1 wrote: jfm - When you do something at work, do you just focus on the main goal or do you also try to optimize the situation by getting other aspects of the work sorted out to obtain the best possible overall result. Of course, the main issue is the cancer phase 1a results right now, and there would be no point in doing a reverse split if they are not good, but if they are, there are any number of other things TH can do to make the overall result even better. I know you are smart enough to want to see those things done too. Yes, let's get the primary result we are looking for but let's also optimize the situation to achieve the reatest benefit.

jfm1330 wrote: You have the right to think wathever you want of me. I don't care. That does not change the reality. This company is old and only game changing results will change how it is perceived. If they have something meaningful in cancer the news will go around easily. They need to come out of the phase Ia with results hinting highly at a proof of concept, and then confirm that in phase Ib.


PWIB123 wrote: I'm sorry jfm1330, but you sound like a severely novice investor.  SPC01 is not wrong about how he views the investment world and the need for THTX leadership to engage capital markets, institutional investors, and retail investors in different ways.  He's not wrong about reverse splits either.  One of my other investments did a reverse split two years ago.  It was a brutal period for them in spite of posting incredible results that no one was investing into, but after the reverse split and consistent communication, the stock has gone from $3/share to $30/share.  It's this simple.  If the results are stunning and literally no one is aware or able to buy, it literally will not matter.  THTX needs us investors to be able to capitalize on the results.  There is an art to this science.  Finance is it's own art form and a foreign language that not everyone speaks.  Same as science.  We need both here.  I've seen it over and over again in my other investments.  THTX is failing us in this regard.  

 




<< Previous
Bullboard Posts
Next >>